Mishani et al., 2002 - Google Patents
Improved method for the quality assurance of [C-11] cholineMishani et al., 2002
- Document ID
- 2351400731032322603
- Author
- Mishani E
- Ben-David I
- Rozen Y
- Publication year
- Publication venue
- Nuclear medicine and biology
External Links
Snippet
[C-11] choline is a very promising radiomarker for the diagnosis of various human tumors using Positron Emission Tomography (PET)[1]. The existing quality control process for [C-11] choline is complicated and combines two HPLC methods with limited separation and …
- 229960001231 Choline 0 title abstract description 41
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8665—Signal analysis for calibrating the measuring apparatus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/38—Flow patterns
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wieder et al. | PET imaging with [18 F] 3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer | |
| Tshibangu et al. | Automated GMP compliant production of [18 F] AlF-NOTA-octreotide | |
| Ryzhikov et al. | Preparation of highly specific radioactivity [18F] flumazenil and its evaluation in cynomolgus monkey by positron emission tomography | |
| Saleem et al. | Pharmacokinetic evaluation of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide in patients by positron emission tomography | |
| Wang et al. | Evaluation of F-18-labeled amino acid derivatives and [18F] FDG as PET probes in a brain tumor-bearing animal model | |
| Sanad et al. | Preparation and biological evaluation of 99mTc N-histamine as a model for brain imaging: in silico study and preclinical evaluation | |
| Rodnick et al. | A fully-automated one-pot synthesis of [18F] fluoromethylcholine with reduced dimethylaminoethanol contamination via [18F] fluoromethyl tosylate | |
| Vaulina et al. | Automated radiosynthesis and purification of [18F] flumazenil with solid phase extraction | |
| Marchand et al. | Automated and efficient radiosynthesis of [18F] FLT using a low amount of precursor | |
| Lindner et al. | Automated production of [18F] SiTATE on a Scintomics GRP™ platform for PET/CT imaging of neuroendocrine tumors | |
| Nishii et al. | Pharmacokinetics, metabolism, biodistribution, radiation dosimetry, and toxicology of 18 F-fluoroacetate (18 F-FACE) in non-human primates | |
| Mishani et al. | Improved method for the quality assurance of [C-11] choline | |
| Chakravarty et al. | 90Y/177Lu‐labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation | |
| Naka et al. | One-pot and one-step automated radio-synthesis of [18F] AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment | |
| Betthauser et al. | Characterization of the radiosynthesis and purification of [18F] THK-5351, a PET ligand for neurofibrillary tau | |
| Humpert et al. | Validation of analytical HPLC with post-column injection as a method for rapid and precise quantification of radiochemical yields | |
| Reischl et al. | Highly efficient automated synthesis of [11C] choline for multi dose utilization | |
| Nishii et al. | Differential Diagnosis between Low‐Grade and High‐Grade Astrocytoma Using System A Amino Acid Transport PET Imaging with C‐11‐MeAIB: A Comparison Study with C‐11‐Methionine PET Imaging | |
| Lee et al. | Early detection of tumor response by FLT/microPET Imaging in a C26 murine colon carcinoma solid tumor animal model | |
| Hellwig et al. | Validation of brain tumour imaging with p-[123 I] iodo-L-phenylalanine and SPECT | |
| Ishiwata et al. | Reliable radiosynthesis of 4-[10 B] borono-2-[18 F] fluoro-l-phenylalanine with quality assurance for boron neutron capture therapy-oriented diagnosis | |
| Dedeurwaerdere et al. | In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat | |
| Waterhouse et al. | Synthesis of [1–11C] Butanol via a facile solid phase extraction protocol | |
| Jiang et al. | Automated radiosynthesis of 1‐(2‐[18F] fluoroethyl)‐L‐tryptophan ([18F] FETrp) for positron emission tomography (PET) imaging of cancer in humans | |
| Jószai et al. | Recommendations for selection of additives for stabilization of [18F] FDG |